Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
Open Access
- 15 February 1997
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 99 (4) , 789-798
- https://doi.org/10.1172/jci119225
Abstract
Somatostatin (SRIF), a hypothalamic inhibitor of pituitary growth hormone (GH) and thyroid-stimulating hormone (TSH) secretion, binds to five distinct receptor (SSTR) subtypes. We therefore tested SSTR subtype-specific SRIF analogs in primary human fetal pituitary cultures (23-25-wk gestation) to elucidate their role in regulating human pituitary function. Using reverse transcription-PCR, mRNA expression of SSTR2 and SSTR5 were detected in fetal pituitary by 25 wk. SRIF analog affinities were determined by membrane radioligand binding in cells stably expressing the human SSTR forms. GH secretion was suppressed equally (40-60%, P < 0.005) by analogs preferential for either SSTR2 (IC50 for receptor binding affinity, 0.19-0.42 nM) or SSTR5 (IC50, 0.37 nM), and compounds with enhanced affinity for SSTR2 were more potent (EC50 for GH suppression, 0.05-0.09 nM) than Lanreotide (EC50, 2.30 nM) and SRIF (EC50, 0.19 nM). Similarly, analogs with high affinity for SSTR2 or SSTR5 decreased TSH secretion (30-40%, P < 0.005). However, prolactin was effectively inhibited only by compounds preferentially bound to SSTR2 (20-30%, P < 0.05). Luteinizing hormone was modestly decreased (15-20%) by SSTR2- or SSTR5-specific analogs. An SSTR5-specific analog also exclusively inhibited GH in acromegalic tumor cells. Thus, SRIF regulation of GH and TSH in primary human fetal pituitary cells is mediated by both SSTR2 and SSTR5, both of which are abundantly expressed by 25 wk. In contrast, suppression of prolactin is mediated mainly by SSTR2. These results indicate that SSTR5 is critical for physiologic regulation of GH and TSH. SRIF analogs with selective affinity for this receptor may therefore be more effective in the treatment of hormone-secreting pituitary adenomas.Keywords
This publication has 58 references indexed in Scilit:
- Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cellsJournal of Endocrinology, 1996
- Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumorsLife Sciences, 1994
- In vitro control of prolactin (PRL) and growth hormone secretion of neonatal rat pituitary glands: Effects of ovine PRL, salmon calcitonin, endothelin-3, angiotensin II, bromocryptine and somatostatinLife Sciences, 1993
- Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brainFEBS Letters, 1993
- Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor SubtypeBiochemical and Biophysical Research Communications, 1993
- Molecular Cloning and Sequencing of a Human Somatostatin Receptor, hSSTR4Biochemical and Biophysical Research Communications, 1993
- Multiple Gene Transcripts of the Somatostatin Receptor SSTR2: Tissue-Selective Distribution and cAMP RegulationBiochemical and Biophysical Research Communications, 1993
- Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells.Journal of Clinical Investigation, 1987
- SomatostatinNew England Journal of Medicine, 1983
- Neurosecretory material passing into the hypophysial portal system in the human infundibulum, and its foetal developmentJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1963